Peter Westervelt

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Donor-Specific Transplant Outcomes from BMTCTN 1702: A Multi-Center Prospective Biological-Assignment Trial

  Blood Advances · 2026-06-05

• Antigen-specific T cell responses to SARS-CoV-2 vaccination after Hematopoietic Cell Transplant or CAR T cell Therapy

  UNC Libraries · 2026-04-16

• Antigen-specific T-cell responses to SARS-CoV-2 vaccination after hematopoietic cell transplant or CAR T-cell therapy

  Blood Advances · 2026-04-06

• Quality of Life and Late Effects Following Haploidentical Vs. Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation: Secondary Analysis of BMT CTN 1702

  Transplantation and Cellular Therapy · 2026-02-01

• Donor Search and Selection Strategy to Facilitate Comparable Transplant Rates across Donor Search Prognosis Groups: A Report from the BMT CTN 1702 Trial

  Transplantation and Cellular Therapy · 2026-01-01

• Access to Allogeneic Cell Transplantation Based on Donor Search Prognosis: BMT CTN 1702 Trial

  Transplantation and Cellular Therapy · 2025-11-08 · 3 citations

• Results from paradigm - a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia

  Blood · 2025-11-03 · 16 citations

• Primary Results From Blood and Marrow Transplant Clinical Trials Network 1702: Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation

  Journal of Clinical Oncology · 2025-09-18 · 10 citations

• Safe and Effective Addition of Ruxolitinib to Graft-versus-host Prophylaxis in Older Adults Undergoing Reduced-intensity Allogeneic Hematopoietic Cell Transplantation

  Transplantation and Cellular Therapy · 2025-08-11 · 1 citations

• Suboptimal Engraftment and Toxicity after Post-Transplant Cyclophosphamide

  Transplantation and Cellular Therapy · 2025-02-01 · 1 citations

• Final Results from BMT CTN 1702 – No Difference in Survival or Other Transplant Outcomes Based on Donor Search Prognosis

  Transplantation and Cellular Therapy · 2025-02-01 · 2 citations

• Itacitinib for prevention of graft-versus-host disease and cytokine release syndrome in haploidentical transplantation

  Blood · 2024-11-22 · 7 citations

• Long Term Outcomes of a Randomized Trial of Anti-T Lymphocyte Globulin to Improve Moderate-Severe Chronic Gvhd Free Survival after Unrelated Donor Hematopoietic Cell Transplantation: A CIBMTR Analysis

  Blood · 2024-11-05

• Clearance of Leukemia Associated Mutations (LAMs) after Induction Therapy Is Associated with Favorable Outcomes in Intermediate Risk Acute Myeloid Leukemia: Interim Results of a Multicenter, Prospective Phase II Trial

  Blood · 2024-11-05 · 1 citations

• Phase 1 Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients with CD7+ T-Cell Non-Hodgkin Lymphoma

  Blood · 2024-11-05 · 1 citations

• Likelihood of finding an 8/8 HLA-matched unrelated donor (Donor Search Prognosis) is not associated with survival: Primary results from BMT CTN 1702

  Blood · 2024-11-05 · 5 citations

• Monitoring clonal burden as an alternative to blast count for myelodysplastic neoplasm treatment response

  Leukemia · 2024-10-04

• Access to Allogeneic Cell Transplantation Based on Donor Search Prognosis: An Interventional TrialPreprint

  medRxiv · 2024-09-16 · 6 citations